secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioRestorative Therapies, Inc. (BRTX)
CIK:        0001505497
Form:       8-K
Filed at:   2026-06-12T21:00:17+00:00
Accession:  0001021771-26-000093
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioRestorative Therapies extends VP R&D Silva's employment; $575K salary unchanged, term to June 2029
--------------------------------------------------------------------------------

- New employment agreement for VP R&D Francisco Silva, effective June 10, 2026, with term through June 10, 2029.
- Salary remains at $575,000 per year; eligible for annual discretionary bonus up to 50% of salary.
- On termination without cause or resignation for good reason, severance equals 1.5x (salary + max bonus), plus COBRA paid for 1.5 years, and full vesting of equity awards.
- Non-compete and non-solicitation covenants apply for 1 year post-termination within US in stem-cell based therapies and biocosmeceuticals.
- Agreement includes assignment of all developments and inventions related to company's business as work made for hire.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505497/000102177126000093/0001021771-26-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505497/000102177126000093/brtx-20260612.htm
  HTML page:      https://secwatch.observer/filing/0001021771-26-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer